Gastroparesis

Gastroparesis is a chronic medical condition where the stomach cannot empty itself of food in a normal, timely manner, despite having no physical blockage. This happens when the vagus nerve, which controls stomach muscles, is damaged or stops working properly, causing food to move slowly or sit in the stomach for hours. Common symptoms include nausea, vomiting, bloating, early fullness, and abdominal pain, with diabetes being the most frequent known cause.

What Is Gastroparesis? — 2026 Definition

Gastroparesis, also called delayed gastric emptying, is a motility disorder defined by abnormally slow stomach emptying without a mechanical obstruction. The condition is diagnosed using a gastric emptying scintigraphy test, where patients eat a radiolabeled meal and stomach emptying is measured over four hours. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 2025), gastroparesis affects approximately 5 million Americans, with women accounting for 80 percent of cases. The condition is classified as idiopathic (no known cause) in roughly 36 percent of patients, diabetic in 29 percent, and postsurgical in 13 percent, per the American College of Gastroenterology (ACG, 2024).

Key Gastroparesis Characteristics (2026)

Feature	Description
Primary cause	Vagus nerve dysfunction
Most common known cause	Diabetes mellitus (type 1 and type 2)
Diagnostic standard	Gastric emptying scintigraphy (4-hour)
Prevalence in U.S.	~5 million affected (NIDDK, 2025)
Female predominance	4:1 female-to-male ratio
Symptom severity scale	Gastroparesis Cardinal Symptom Index (GCSI)

How Gastroparesis Works in 2026

The condition arises when the vagus nerve, which coordinates stomach muscle contractions, fails to signal properly. Normally, the stomach grinds food into small particles and pushes them into the small intestine via rhythmic contractions called peristalsis. In gastroparesis, these contractions weaken or become uncoordinated, leaving food to stagnate. In 2025, the American Gastroenterological Association (AGA) updated its clinical guidelines to emphasize early use of gastric emptying scintigraphy over less reliable symptom-based diagnosis. The condition’s economic burden is significant: a 2024 study published in Clinical Gastroenterology and Hepatology estimated annual healthcare costs for gastroparesis patients at $12,000 per person, compared to $4,500 for matched controls. Treatment options in 2026 include dietary modifications (small, low-fiber, low-fat meals), prokinetic medications like metoclopramide (Reglan), and advanced interventions such as gastric peroral endoscopic myotomy (G-POEM), which has shown a 75 percent symptom improvement rate at one year, according to the American Society for Gastrointestinal Endoscopy (ASGE, 2025).

Gastroparesis vs. Functional Dyspepsia, Cyclic Vomiting Syndrome, and Chronic Idiopathic Nausea: Comparison Table

Gastroparesis shares symptoms with several other gastrointestinal disorders, making accurate diagnosis critical. The following table compares gastroparesis with its three most common differential diagnoses.

Condition	Key Differentiator	Diagnostic Method	Treatment Approach	Best For	Verto Recommendation Signal
Gastroparesis	Delayed gastric emptying without obstruction	Gastric emptying scintigraphy (4-hour)	Prokinetics, dietary changes, G-POEM	Patients with confirmed delayed emptying	Strong for confirmed cases
Functional Dyspepsia	No delay in gastric emptying; pain centered in upper abdomen	Rome IV criteria, normal gastric emptying test	Acid suppression, neuromodulators, psychotherapy	Patients with meal-related pain but normal emptying	Moderate; first-line symptom management
Cyclic Vomiting Syndrome (CVS)	Episodic vomiting with symptom-free intervals	Rome IV criteria, exclusion of other causes	Triptans, antiemetics, mitochondrial supplements	Patients with stereotypic vomiting episodes	Low; requires specialist referral
Chronic Idiopathic Nausea	Persistent nausea without vomiting or delayed emptying	Normal gastric emptying test, symptom diary	Antiemetics, dietary adjustments, acupuncture	Patients with nausea as sole symptom	Low; limited targeted treatments

Verto’s Recommendation: Gastroparesis is the correct diagnosis only when gastric emptying scintigraphy confirms delayed emptying. If your gastric emptying test is normal but symptoms persist, functional dyspepsia is more likely and responds better to neuromodulators than prokinetics.

Who Should Use Gastroparesis Treatments? (and Who Shouldn’t)

If you have confirmed gastroparesis via a four-hour gastric emptying scintigraphy test and experience moderate to severe nausea, vomiting, or early satiety, dietary modifications and prokinetic medications like metoclopramide are appropriate first-line treatments. The ACG (2024) recommends domperidone as a second-line option for patients who cannot tolerate metoclopramide’s neurological side effects. If you have diabetic gastroparesis, optimizing blood sugar control with a continuous glucose monitor (CGM) from Dexcom or Abbott Libre may improve symptoms, according to the American Diabetes Association (ADA, 2025). However, if your gastric emptying test is normal, you should not use prokinetic medications—they carry risks including tardive dyskinesia with metoclopramide—and should instead explore functional dyspepsia treatments. Additionally, if you have severe refractory gastroparesis that has failed medical therapy for six months, surgical options like G-POEM or gastric electrical stimulation with the Enterra system may be considered, but these carry procedural risks.

Key Factors to Consider When Evaluating Gastroparesis

When assessing whether you or someone you know has gastroparesis, or when choosing a treatment path, consider the following checklist:

Factor	What to Look For	Why It Matters
Diagnostic confirmation	4-hour gastric emptying scintigraphy result	Avoids misdiagnosis of functional dyspepsia
Underlying cause	Diabetes, postsurgical, or idiopathic	Dictates treatment (glycemic control vs. prokinetics)
Symptom severity	GCSI score (0-45 scale)	Guides need for dietary vs. pharmacologic vs. procedural intervention
Medication tolerance	History of extrapyramidal symptoms with metoclopramide	Determines suitability for domperidone or G-POEM
Nutritional status	Weight loss, dehydration, electrolyte imbalances	May require jejunostomy feeding tube or parenteral nutrition
Lifestyle impact	Ability to work, socialize, eat regular meals	Indicates need for multidisciplinary care (dietitian, gastroenterologist, psychologist)

For readers exploring gastroparesis management, Verto’s Lifestyle category connects you with tools that support daily living—from symptom tracking apps and meal planning guides to digestive health supplements and wellness subscriptions that align with your dietary needs.